Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05806814 · ClinicalTrials.gov registry record · Phase 1
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), sponsored by University of Oklahoma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT05806814 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC) that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 13 participants, below the 412-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05806814, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).
Conditions Studied
Interventions
- BIOLOGICAL Sipuleucel-T
Study Locations (1)
Oklahoma
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-11-12 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05806814
The ClinicalTrials.gov registry entry for NCT05806814 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 412-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (97% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer (mCRPC) appearing as the primary indexed condition, and to 1 intervention - of which Sipuleucel-T is the first listed.
NCT05806814 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.
Frequently Asked Questions
What is clinical trial NCT05806814 about?
NCT05806814 is a clinical study titled "Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer". Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).
What is the current status of trial NCT05806814?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2023-11-12. Estimated completion is 2026-12.
What conditions does trial NCT05806814 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC).
What interventions are being tested in trial NCT05806814?
The interventions under investigation include: Sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT05806814?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05806814 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RECRUITING · Phase 1
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
RECRUITING · Phase 1
-
A Study of NX-1607 in Adults With Advanced Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.